Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)

Trial Profile

Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Pitavastatin (Primary)
  • Indications Asthenia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms PREPARE
  • Most Recent Events

    • 21 Feb 2018 Planned End Date changed from 28 Feb 2023 to 28 Feb 2022.
    • 21 Feb 2018 Planned primary completion date changed from 28 Feb 2023 to 28 Feb 2022.
    • 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top